Karyopharm Therapeutics, Inc. (NASDAQ:KPTI) Q3 2019 Earnings Conference Call - Final Transcript
Nov 04, 2019 • 08:30 am ET
Good morning, my name is Chris and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics' Third Quarter 2019 Financial Results Conference Call. There will be a question-and-answer session to follow. [Operator Instructions]. I would now like to turn the call over to Mr. Ian Karp, Karyopharm's, Vice President, Investor and Public Relations.
Thank you, Chris, and thank you all for joining us on today's conference call to discuss Karyopharm's Third Quarter 2019 Financial Results and Business Update. This is Ian Karp, and I'm joined today by Dr. Michael Kauffman, our Chief Executive Officer; Dr. Sharon Shacham, President and Chief Scientific Officer; Mr. Mike Mason, Chief Financial Officer; Mr. Chris Primiano, Chief Business Officer and General Counsel; Mr. Perry Monaco, Senior Vice President of Sales; and Dr. Jatin Shah, Chief Medical Officer.
On the call today Dr. Kauffman will provide an overview of key recent corporate developments. Perry will give an update on the initial commercial launch of XPOVIO and Mike will highlight the third quarter 2019 financial results. We will conclude with a Q&A portion of the call. Earlier this morning we issued a press release detailing Karyopharm's results for the third quarter 2019. This release as well as an accompanying slide presentation are available on our website at karyopharm.com.
Before we begin our formal comments, for those following along in the slide presentation, please turn to slide 3, and I'll remind you that various remarks we will make today constitute forward-looking statements for purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995.
These include statements about future expectations, clinical developments and regulatory matters and timelines. The potential success of our products and product candidates, including our expectations relating to the commercialization of XPOVIO, financial projections and our plans and prospects. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our most recently Quarterly Report on Form 10-Q, which is on file with the SEC, and in other filings that we may make with the SEC in the future.
Any forward-looking statements represent our views as of today only. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so even if our views change. Therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.
In addition, please note that any references we make to clinical trial data during today's discussion refer to interim unaudited site data, unless otherwise specified. We will also be providing on this call non-GAAP outlook for operating expense for 2019, which can only be provided on a non-GAAP basis without unreasonable efforts.
I'll now turn the call over to Dr. Michael Kauffman, Chief Executive Officer, and please now turn to slide number 4.
Michael G. Kauffman
Thank you, Ian and